A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2013
At a glance
- Drugs Afatinib; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Jul 2012 Planned number of patients changed from 30 to 40 as reported by European Clinical Trials Database.
- 03 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.